BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 33994538)

  • 1. Editorial: mRNA Vaccines and Immunotherapy in Oncology: A New Era for Personalized Medicine.
    Parums DV
    Med Sci Monit; 2021 May; 27():e933088. PubMed ID: 33994538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRNA vaccine for cancer immunotherapy.
    Miao L; Zhang Y; Huang L
    Mol Cancer; 2021 Feb; 20(1):41. PubMed ID: 33632261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy.
    Copur M
    Oncology (Williston Park); 2021 Apr; 35(4):190-198. PubMed ID: 33893760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immunological effects of mRNA vaccines in malignant diseases.
    Heine A; Juranek S; Brossart P
    Mol Cancer; 2021 Mar; 20(1):52. PubMed ID: 33722265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.
    Bendjama K; Quemeneur E
    Hum Vaccin Immunother; 2017 Sep; 13(9):1997-2003. PubMed ID: 28846477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.
    Nakajima H; Nakatsura T
    Immunol Med; 2021 Mar; 44(1):10-15. PubMed ID: 32643578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination.
    Sun X; Zeng L; Huang Y
    J Gene Med; 2019 Jul; 21(7):e3089. PubMed ID: 30958606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.
    Shemesh CS; Hsu JC; Hosseini I; Shen BQ; Rotte A; Twomey P; Girish S; Wu B
    Mol Ther; 2021 Feb; 29(2):555-570. PubMed ID: 33038322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer neoantigen: Boosting immunotherapy.
    Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA-based dendritic cell vaccines.
    Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
    Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines.
    Lin F; Lin EZ; Anekoji M; Ichim TE; Hu J; Marincola FM; Jones LD; Kesari S; Ashili S
    J Transl Med; 2023 Nov; 21(1):830. PubMed ID: 37978542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized cancer vaccines: adjuvants are important, too.
    Gouttefangeas C; Rammensee HG
    Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.